Biohaven Ltd. Debt Securities, Realized Gain (Loss)
Biohaven Ltd. (BHVN) reported Debt Securities, Realized Gain (Loss) of $0 for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Income Statement › Other Income
us-gaap:DebtSecuritiesRealizedGainLoss · last filed 2023-11-14
- Biohaven Ltd. debt securities, realized gain (loss) for the quarter ending 2023-09-30 was $0.00.
- Biohaven Ltd. debt securities, realized gain (loss) for the quarter ending 2023-06-30 was -$17.00K.
- Biohaven Ltd. debt securities, realized gain (loss) for the quarter ending 2023-03-31 was -$21.00K.
| Period end | Debt Securities, Realized Gain (Loss) 3 month | Debt Securities, Realized Gain (Loss) 6 month | Debt Securities, Realized Gain (Loss) 9 month |
|---|---|---|---|
| 2023-09-30 | $0.00 10-Q · filed 2023-11-14 | -$17.00K derived: sum of 2 quarters · filed 2023-11-14 | -$39.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$17.00K 10-Q · filed 2023-07-31 | -$39.00K 10-Q · filed 2023-07-31 | |
| 2023-03-31 | -$21.00K 10-Q · filed 2023-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |